ALK-N001 / Affinity Biopharma, Zhejiang Anglikang Pharmaceutical - LARVOL DELTA

A Phase IIa Study Evaluating Injectable ALK-N001 in Patients With Advanced Gastrointestinal Tumors (clinicaltrials.gov) - P2 | N=174 | Not yet recruiting | Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd.

New P2 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=16 | Suspended | Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd.

First-in-human • New P1 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Hepatocellular Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=190 | Not yet recruiting | Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd.

New P1/2 trial • Breast Cancer • Esophageal Cancer • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • HER-2